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Managing pain is a vast clinical challenge. The 
lack of side-effect–free analgesics has contributed 
to the recent opioid abuse tragedy, and life ex-
pectancy in the United States has fallen as a re-
sult. The urgency of the situation demands a 
major effort to identify new approaches to the 
treatment of pain. Repurposed Food and Drug 
Administration (FDA)–approved drugs with an-
algesic efficacy could be useful, given the lengthy 
drug-development process. Therefore, the work 
of Salvemini and coworkers (Stockstill et al.) is 
notable in unraveling the mechanisms that con-
tribute to the neuropathic pain caused by bortez-
omib, an anticancer medication.1
Bortezomib contributes to the success of can-
cer treatment and the long-term survival of pa-
tients with multiple myeloma. This modified 
dipeptide binds and inhibits the 26S proteasome 
(a cytosolic protein complex that breaks down 
proteins) and fuels the apoptotic mechanisms 
that kill myeloma cells. Unfortunately, it also 
causes painful peripheral neuropathy in approxi-
mately 30% of patients, and in some cases this 
has led to discontinuation of treatment. A causal 
link between sphingolipids (such as sphingosine-1 
phosphate) and neuropathic pain has been found 
in many studies in rodents. In addition, some 
mutations in the genes SPTLC1 and SPTLC2 — 
which encode serine palmitoyltransferase, an 
enzyme that in turn drives de novo synthesis of 
sphingolipids — lead to neuropathic pain in 
humans because of the production of a neuro-
toxic sphingoid metabolite. Studies in animals, 
including unbiased metabolomic studies of neu-
ropathic pain mechanisms in the spinal cord, 
have highlighted the importance of this enzyme 
in neuropathic pain.2,3 Because the levels of the 
proapoptotic lipid ceramide are up-regulated by 
bortezomib, and because ceramide is a precur-
sor of sphingolipids and would therefore be ex-
pected to increase the levels of sphingosine, it 
was logical to investigate the association between 
the use of bortezomib and levels of sphingolipid 
metabolites.
In studies in rats, Salvemini and coworkers 
investigated the effect of the drug on the dorsal 
horn of the spinal cord, where primary afferent 
neurons impart information to the central ner-
vous system. They observed higher levels of both 
ceramide and sphingosine derivatives such as 
sphingosine-1 phosphate, and they found that 
blockade of serine palmitoyltransferase reversed 
bortezomib-induced neuropathic pain. These data 
confirmed a role for sphingolipids in some of 
the undesirable side effects of bortezomib.
Serendipitously, an orally active functional an-
tagonist of sphingosine-1 phosphate, fingolimod, 
is already in clinical use. Fingolimod impedes 
lymphocyte egress from lymph nodes into the 
central nervous system. It is a useful oral drug 
for the treatment of multiple sclerosis. Known 
for more than a decade to have analgesic proper-
ties,4 it down-regulates S1PR1, one of the five 
G-protein–coupled receptors activated by sphin-
gosine-1 phosphate. Salvemini’s team found that 
a specific S1PR1 antagonist reversed neuropathic 
pain and that silencing S1PR1 with the use of 
small interfering RNA confirmed its role in 
mediating pain in animal models. Fingolimod is 
thus a potentially useful treatment for bortezo-
mib-induced neuropathic pain in humans — but 
might it compromise the desirable antitumor 
actions of bortezomib? High doses of fingoli-
mod had no such effect in an in vitro model of 
tumor-cell killing, and indeed fingolimod itself 
has some antitumor activity. A proof-of-concept 
trial of the effects of fingolimod on bortezomib-
induced neuropathic pain in humans therefore 
seems justified.
How does altered sphingolipid metabolism 
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lead to neuropathic pain? S1PR1 is found at high 
levels in astrocytes (Fig. 1), and bortezomib in-
duces the expression of glial fibrillary acidic 
protein in the dorsal horn of the spinal cord, 
which suggests an increase in the number or 
activation (or both) of astrocytes. Mice that lack 
S1PR1 specifically in astrocytes show little neu-
ropathic pain on bortezomib treatment. It seems 
that activated astrocytes (which synthesize and 
secrete the neurotransmitter molecule glutamate) 
excite the dorsal horn. Also supporting this hy-
pothesis is the finding that miniature excitatory 
postsynaptic currents in neurons of the dorsal 
horn increased in both frequency and amplitude 
in bortezomib-treated rats. S1PR1 agonists ap-
plied to the spinal cord also increased the fre-
quency of these glutamatergic events. Future 
areas of investigation include the mechanism 
Figure 1. Astrocytes, Pain, and Bortezomib — A Model.
Within astrocytes, bortezomib causes an increase in sphingolipid metabolism, leading to an increase in the production of ceramide as 
well as sphingosine-1 phosphate (S1P) and dihydrosphingosine-1-phosphate (DH-S1P). Within the periphery, bortezomib increases the 
production of tumor necrosis factor α (TNF-α) and interleukin-1β, which in turn act to augment sphingolipid metabolism within astro-
cytes. Released S1P binds to the S1P receptor (S1PR1) on astrocytes, which ultimately leads to an increase in the release of presynaptic 
glutamate at the level of the dorsal horn of the spinal cord and to the development of neuropathic pain. Inhibition of S1PR1 by phosphory-
lated fingolimod reduces the release of presynaptic glutamate and therefore reduces neuropathic pain. GFAP denotes glial fibrillary acidic 
protein.
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through which S1PR1 activation in astrocytes 
leads to glutamatergic signaling, other potential 
mechanisms through which bortezomib causes 
neuropathic pain, and the question of whether 
fingolimod has any effect on neuropathy. The 
fascinating story of bortezomib-evoked pain 
provides a glimmer of hope that fingolimod 
might, in some persons, mitigate chronic pain.5
Disclosure forms provided by the authors are available with 
the full text of this article at NEJM.org.
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